P&G saw three new federal suits that center on allegedly deceptive environmental claims on its Charmin and Puffs paper ...

The FDA is requiring COVID vaccine makers Pfizer and Moderna to update their warnings about the possible risk of myocarditis ...

Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Pfizer PFE shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning. Still, Pfizer stock has fallen 10% year to date ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

The Biomedical Advanced Research and Development Authority (BARDA) has axed a Project NextGen (PNG) award for GeoVax ... previously received an approved Pfizer or Moderna mRNA vaccine.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...